Litcius/Paper detail

EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature

Ullas Batra, Mansi Sharma, B. P. Amrith, Anurag Mehta, Praveen Jain

2020Clinical Lung Cancer25 citationsDOI

Topics & Concepts

OsimertinibAlectinibMedicineLung cancerCeritinibOncologyCrizotinibAnaplastic lymphoma kinaseEpidermal growth factor receptorFusion geneClinical trialInternal medicineAcquired resistanceCancer researchErlotinibCancerGeneGeneticsMalignant pleural effusionBiologyLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms
EML4-ALK Fusion as a Resistance Mechanism to Osimertinib and Its Successful Management With Osimertinib and Alectinib: Case Report and Review of the Literature | Litcius